 |
 |
PharmaVOICE - January 2009 Partnering for Success By Robin Robinson Increasing pressure on internal funding for R&D has created a reinvigorated focus on strategic alliances in the industry. The uncertainty of a new administration, the ever-present threat of patent expiry, and the financial crisis sweeping the world have put more weight on these collaborations to be successful. Our industry leaders discuss the challenges, best practices, and strategies they use to ensure partnerships function at their best. Sidebars Best Practices Managing High-Performance Partnerships 10 Key Facts to Know About Strategic Alliances Experts on this Topic Harry Atkins. Senior Director, Alliance Management, Endo Pharmaceuticals Inc., a specialty pharmaceutical company engaged in the research, development, and marketing of branded and generic prescription pharmaceuticals used primarily to treat and manage pain. For more information, visit endo.com. Kimberly Brue. Director, Alliance Management, Sanofi Pasteur, the vaccines division of Sanofi-Aventis Group, which offers a range of vaccines that protect against 20 infectious diseases. For more information, visit sanofipasteur.us. Gary A. Gabrielsen. VP, Business Development, Astellas US LLC, an affiliate of Astellas Pharma Inc., which is dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, visit us.astellas.com. Jeff Greene. Transaction Advisory Leader Global Pharma Center, Ernst & Young, which helps organizations execute the right alliances, access funding, and gain insight into the market and regulatory environment of today’s dynamic health-sciences market. For more information, visit ey.com. Anthony Hörning. Head Global Alliance Management, Novartis Pharma AG, which provides medicines to treat and prevent diseases, ease suffering, and improve quality of life. For more information, visit pharma.us.novartis.com. Michael Leonetti. Head of Healthcare Partnerships, Boehringer Ingelheim, the largest U.S. subsidiary of Boehringer Ingelheim Corp. and a member of the Boehringer Ingelheim group of companies, one of the world’s 20 leading pharmaceutical companies. For more information, visit us.boehringer-ingelheim.com. Mr. Leonetti also serves as Chairman of the Association of Strategic Alliance Professionals (ASAP) and heads ASAP’s BioPharma Council. For more information, please visit strategic-alliances.org. Sara Melo-Pereira. Director of Global Marketing, Skila, a provider of knowledge-driven management solutions for the pharma industry, including alliance management. For more information, visit skila.com or e-mail saramelo-pereira@skila.com. Bill Shew. Senior Principal, Product and Portfolio Strategy, IMS, which works with global pharmaceutical, biotech, device, and diagnostic companies to meet competitive challenges. For more information, visit imshealth.com. Karl Wassmann. CEO, Source MDx, a privately held molecular diagnostics development company that monitors an individual’s health, disease status, and response to therapy using RNA from whole blood or tissue samples. For more information, visit sourcemdx.com. Daniel Zabrowski, Ph.D. Global Head, Pharma Partnering, Roche, part of the Roche Group, a research-oriented healthcare group with core businesses in pharmaceuticals and diagnostics. For more information, visit rocheusa.com.
|
